This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
overfunded
Ammique
172%
Raised
£861,360
Investors
187
Target
£500,000
Equity
14.70%
Pre-money valuation
£5,000,000

Ammique has designed and created an innovative and adaptive, hygienic sleep system. With additional refinements in the next phase, Ammique is aiming to meet the growing global demand for premium beds, and for better sleep, health and well-being.

  • Fully tested technology. Lifetime warranty of body contouring support
  • IP protected with a number of patents and trademarks in place
  • Global mattress market currently valued at £19 billion
  • The global sleep market is estimated to reach £65 billion by 2020.

Idea

Our research showed that the bed industry failed to meet our needs, so we set out to design a superior bed. The result is our mattress-less and precision engineered Ammique sleep system, which provides the highest levels of body contouring support and hygiene - with a lifetime guarantee.

The global sleep market is estimated to reach £65 billion by 2020. We now intend to revolutionize the sleep industry. Brand extensions aim to be rolled out over time increasing brand value and revenue streams. All our products are designed to be environmentally sustainable and all materials are sourced ethically.

Progress:

1. International patents and trademarks have been granted and new PCT patents are pending

2. First generation beds have been made, sold and field trialed in the UK and the US in boutique hotels and in private homes. Second gen beds are ready to be made and sold.

3. Our market test run indicated significant consumer demand for a better bed and gained media interest in Ammique

4. Two shows of first gen Ammique beds in UK and US were extended to a total of three UK and six US shows; instigated by invitation of the event organizers and heavily subsidized by them

5. Rigorous independent testing, carried out by the FIRA, where the durability of the bed base was tested for 250k cycles.

“The Ammique bed - there’s no question that it lives up to the hype” Sue d’Arcy, The Sunday Times

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Ammique pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Ammique has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.